Infinity Pharmaceuticals, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2019-12-17: Study NCT03961698; Company role Lead sponsor; Phase Phase 2; Status Unknown.
- 2019-09-25: Study NCT03980041; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2018-10-15: Study NCT03719326; Company role Collaborator; Phase Phase 1; Status Completed.
- 2016-07: Study NCT02640833; Company role Collaborator; Phase Phase 1; Status Withdrawn.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2019-12-17 | NCT03961698 Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma | Lead sponsor | Phase 2 | Unknown | Breast Cancer; Renal Cell Carcinoma | 91 | 2023-08-31 |
| 2019-09-25 | NCT03980041 Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | Lead sponsor | Phase 2 | Completed | Bladder Cancer; Urothelial Carcinoma; Solid Tumor; Advanced Cancer | 49 | 2022-11-15 |
| 2018-10-15 | NCT03719326 A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | Collaborator Lead: Arcus Biosciences, Inc. | Phase 1 | Completed | TNBC - Triple-Negative Breast Cancer; Ovarian Cancer | 35 | 2021-07-02 |
| 2016-07 | NCT02640833 A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor | Collaborator Lead: AbbVie | Phase 1 | Withdrawn | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Non-Hodgkin Lymphoma | 0 | 2021-02 |
| 2015-12 | NCT02637531 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | Lead sponsor | Phase 1 | Unknown | Advanced Solid Tumors (Part A/B/C/D); Non-small Cell Lung Cancer (Part E); Melanoma (Part E); Squamous Cell Cancer of the Head and Neck (Part E); Triple Negative Breast Cancer (Part F); Adrenocortical Carcinoma (Part G); Mesothelioma (Part G); High-circulating Myeloid-derived Suppressor Cells (Part H) | 219 | 2022-12 |
| 2015-11 | NCT02598570 Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma | Collaborator Lead: AbbVie | Phase 1 | Completed | Lymphoma | 7 | 2017-02 |
| 2013-12 | NCT02028039 IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) | Collaborator Lead: M.D. Anderson Cancer Center | Phase 2 | Withdrawn | Leukemia | 0 | |
| 2013-05 | NCT01871675 Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | Collaborator Lead: SCRI Development Innovations, LLC | Phase 1 | Completed | Lymphoma; Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma; T-cell Lymphoma | 48 | 2016-06 |
| 2012-03 | NCT01609179 IPI-926 Extension Protocol for Continuation of Treatment With IPI-926 | Lead sponsor | Not applicable | Completed | Basal Cell Carcinoma; Chondrosarcoma | 9 | 2012-11 |
| 2011-10 | NCT01371617 A Phase 2 Study With IPI-926 in Patients With Myelofibrosis | Lead sponsor | Phase 2 | Completed | Primary Myelofibrosis; Fibrosis, Bone Marrow | 14 | 2012-08 |
| 2011-08-23 | NCT01383538 FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma | Collaborator Lead: Andrew Ko | Phase 1 | Completed | Pancreatic Cancer; Adenocarcinoma; Pancreatic Neoplasms | 15 | 2015-05-26 |
| 2011-07 | NCT01427946 Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer | Lead sponsor | Phase 1, Phase 2 | Completed | Non-small Cell Lung Cancer | 47 | 2014-10 |
| 2011-05 | NCT01362400 A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer | Lead sponsor | Phase 2 | Completed | Non Small Cell Lung Cancer | 226 | 2014-04 |
| 2011-02 | NCT01310816 A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma | Lead sponsor | Phase 2 | Completed | Conventional Chondrosarcoma | 105 | 2013-12 |
| 2010-10 | NCT01228435 IPI-504 in NSCLC Patients With ALK Translocations | Collaborator Lead: Massachusetts General Hospital | Phase 2 | Terminated Results posted | Lung Cancer; Stage IIIb Lung Cancer; Stage IV Lung Cancer | 3 | 2012-02 |
| 2010-06 | NCT01193491 Dose Escalation of IPI-493 in Hematologic Malignancies | Lead sponsor | Phase 1 | Terminated | Hematologic Malignancies | 4 | 2011-07 |
| 2010-04 | NCT01130142 A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer | Lead sponsor | Phase 1, Phase 2 | Completed | Metastatic Pancreatic Cancer | 122 | 2012-05 |
| 2010-01 | NCT00969917 Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma | Lead sponsor | Phase 2 | Withdrawn | Dedifferentiated Liposarcoma | 0 | 2010-12 |
| 2009-03 | NCT00817362 Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer | Lead sponsor | Phase 2 | Terminated | Breast Cancer; HER2 Positive Breast Cancer; Metastatic Breast Cancer; Cancer of the Breast | 29 | 2011-05 |
| 2008-09 | NCT00761696 A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies | Lead sponsor | Phase 1 | Completed | Neoplasms | 94 | 2012-04 |
| 2008-08 | NCT00688766 Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib | Lead sponsor | Phase 3 | Terminated | Gastrointestinal Stromal Tumors | 47 | 2009-05 |
| 2008-07 | NCT00724425 A Phase 1 Dose Escalation Study of IPI-493 | Lead sponsor | Phase 1 | Terminated | Advanced Malignancies | 53 | 2011-07 |
| 2008-02 | NCT00627419 A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma | Lead sponsor | Phase 2 | Terminated | Metastatic Melanoma | 1 | 2009-10 |
| 2007-12 | NCT00606814 Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors | Lead sponsor | Phase 1 | Completed | Solid Tumors | 60 | 2011-12 |
| 2007-11 | NCT00564928 A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer | Lead sponsor | Phase 2 | Completed | Prostate Cancer; Prostatic Neoplasms; Cancer of the Prostate | 19 | 2010-07 |
| 2007-01 | NCT00431015 Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) | Lead sponsor | Phase 1, Phase 2 | Completed | Lung Cancer | 88 | 2011-12 |
| 2005-12 | NCT00276302 Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) | Lead sponsor | Phase 1 | Completed | Gastrointestinal Stromal Tumors; Soft Tissue Sarcomas | 63 | 2010-11 |
| 2005-06 | NCT00113204 Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma | Lead sponsor | Phase 1 | Completed | Multiple Myeloma | 18 | 2007-03 |